Partnership - Octagenix

Our most recent partnership

OctaGenix® has recently teamed up with KVK™️ Tech, a US company based in Newtown, Pennsylvania, for the supply of their high-quality, FDA-approved medicines that address unmet NHS needs. OctaGenix and KVK™️ Tech are on a mission to bring affordable and safe medications to the global markets for combating obesity. The first phase is to launch a range of anorectic products to control obesity in the UK, Asia, and Europe.

OctaGenix® is keen to find new medicine and identify the best solutions to improve the value of our healthcare system. By partnering with the brightest minds in innovative research focus organizations, we are able to achieve our goals of bringing quality products and innovative treatments to patients. We are actively seeking potential partners to join us on our exhilarating journey of contributing to the welfare of patients.

Our ideal partners will share our corporate philosophy of enriching people’s dignity, quality of life, and overall wellbeing. We strongly believe that, with the right partners, we will be able to revolutionize the existing standards of health and care.

Obesity Pandemic in the UK

The obesity pandemic lies with the fact that far too little has been understood about the psychological demons that enshroud obesity. The Royal College of Physicians made some headway in this respect when it announced in January 2019 that; obesity has to be urgently recognised as a disease by the government and the broader health sector and warning that until this happens, its prevalence is unlikely to be reduced”.

In its website VLOG, Professor Andrew Goddard explained, “how we condition our brain to think about appetite is all very much based in science” However, when it comes to “joining the dots” regarding the solution, the public is left without the full toolkit to be able to act effectively.

Why We Need to Treat Obesity?

In 2019, in England, 876,000 hospital admissions were related to obesity, costing NHS over 68% of the total drug spent of £18.6 Billion in secondary and tertiary care. The spending was on top of the GP surgery prescribing for the management of obesity in the community. The big chunk of £12.6 Billion, which was spent directly on obesity, was linked to managing numerous endocrine disorders, including over 13 cancers, insulinoma, diabetes, Cushing’s syndrome, hypothyroidism, polycystic ovarian syndrome, and pituitary disorders, e.g., growth hormone deficiency.

Obesity and the need of a medical intervention

The NHS embraces the role of nutrition and calorie-controlled diet plus exercise as if this simple, “hey presto formula” could blindly be followed to create the winning solution. The NHS is also promoting a more self-help approach to obesity through educational programs, which of course is laudable, but these initiatives are proving to be “sticking plaster solutions” rather than surgery to a massive problem. Research suggests that 90% of the people with obesity have made serious attempts to lose weight but without any medical interventions, the compliance remains very poor, therefore, medical intervention is required to aid adherence to controlled calorie intake.

Why Is It So Hard to Lose Weight?

One of the reasons why it is so hard to lose weight is because changes in your appetite hormone levels make it difficult to lose weight and keep it off. When we lose weight, our body’s natural response includes an increase in a key hunger hormone and a decrease in fullness hormones, undermining your ability to lose weight and keep it off.

COVID-19 Related Death Due to the Obesity

Like many other serious illnesses, Covid19 has also shown how obesity increases the body’s vulnerability, and it’s another wake-up call which one assumes will, at last, be properly, heeded especially, as it’s understood to have contributed to the near-death experience endured by American president Donald Trump and UK’s Prime Minister Boris Johnson.

Obesity Rates

The problem of obesity is more serious than we have ever envisaged. The rates of obesity are increasing faster than ever before, today in the UK, the majority of adults are overweight, 67% of men and 60% of women, whereas 26% of men and 29% of women are “clinically obese”, with obesity being such a massive problem for the NHS and the UK, only one NICE recommended medical treatment “Orlistat” is available for the NHS. As you would expect with any pharmaceutical product, “Orlistat” treatment doesn’t work for everyone; therefore, obesity-related ailments are on the rise, resulting in severer financial crises and deficits for many NHS trusts in the UK. These financial crises have led to a new advent of control whereby financiers and accountants are making the clinical decisions, hence restricting the patient access to medicine and innovative treatments, which in turn has triggered an increase in both the morbidity and mortality rates.

More than ever before we now feel compelled to highlight a vital missing tool, which can act as an all-important psychological “trigger” towards significant weight-loss.

Men

0 %

Women

0 %

Anorectics

“Anorectics” are a drug type that work in the hypothalamus, reducing the perception of hunger, resulting in lower food consumption, thereby leading to weight loss.

Anorectic agents, both Phentermine and Diethylpropion, have been for use in the UK, as specials, since 2000. Currently, there is over 12.5 million tablets usage of both the compounds.

By bringing a licensed product, OctaGenix^® Limited is aiming to improve the safe usage of Anorectics in the UK. Our leading brand Lomaira™️, which is half of the strength of the lowest strength Phentermine available as specials, has shown comparable clinical effectiveness, with a much better safety profile.

Phentermine

In 1959 a drug called Phentermine; was launched in the US, and due to the safety profile of the drug, it has never withdrawn from the market, and it remained the nation’s leading “anorectics” (appetite suppressant) class drug ever since. In the UK, Phentermine has been in use for over two decades, as Specials, in tablet and capsule formulations. Currently, there is an excess of 6.8 million dosages usage per annum of Phentermine, which is unusually high for a Specials type product. OctaGenix^® Limited and KVK™️ Tech. Inc. has signed an agreement to bring four formulations of Phentermine to overcome the safety risks, which may be associated with the use of Specials.

Diethylpropion

Diethylpropion or Amfepramone is an appetite suppressant considered to produce less central nervous system disturbance than most anorectic drugs. The compound is also considered to be among the safest for patients with hypertension.

Most recently, after being withdrawn from the various EU markets, Diethylpropion is once again getting popularity due to its safety profile. Today, Diethylpropion is available in Germany, Denmark, Romania and, as Specials in the UK, there is a usage of more than 5.6 Million tablets per annum.

OctaGenix^® Limited and KVK™️ Tech. Inc. has signed the agreement to bring two strengths of Diethylpropion to overcome the safety risks, which may be associated with the use of Specials.

Lomaira

Lomaira is an appetite suppressant available by prescription only and used for a short period of time for weight reduction in adults with an initial BMI of ≥30 or ≥27 with at least one weight-related medical condition such as controlled high blood pressure, diabetes, or high cholesterol. Lomaira should be used together with increased physical activity and a reduced-calorie diet. Lomaira is can be used up to 3x daily, 30 minutes before meals.

Lomaira’s flexible dosing and quick onset of action makes it a perfect choice for busy lifestyles. Lomaira has a unique ability to suppress appetite when patients need it the most.